Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2017-10-06
Target enrollment:
Participant gender:
Summary
This is a Phase 2, therapeutic-exploratory, adaptive design, open-label, multicenter,
multinational study evaluating neratinib monotherapy and neratinib plus temsirolimus
combination therapy in patients with non-small cell lung cancer (NSCLC) who have documented
somatic HER2 mutations.